SGMT vs. SVRA, ANNX, SIGA, TRDA, YMAB, CYRX, AVTE, FULC, CDMO, and APLT
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Savara (SVRA), Annexon (ANNX), SIGA Technologies (SIGA), Entrada Therapeutics (TRDA), Y-mAbs Therapeutics (YMAB), Cryoport (CYRX), Aerovate Therapeutics (AVTE), Fulcrum Therapeutics (FULC), Avid Bioservices (CDMO), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
Sagimet Biosciences has higher revenue and earnings than Savara.
87.9% of Savara shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.1% of Savara shares are owned by insiders. Comparatively, 17.6% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Sagimet Biosciences' return on equity of -51.95% beat Savara's return on equity.
In the previous week, Sagimet Biosciences had 5 more articles in the media than Savara. MarketBeat recorded 7 mentions for Sagimet Biosciences and 2 mentions for Savara. Savara's average media sentiment score of 0.38 beat Sagimet Biosciences' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the news media.
Savara received 270 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 66.06% of users gave Savara an outperform vote.
Savara presently has a consensus price target of $9.17, suggesting a potential upside of 131.48%. Sagimet Biosciences has a consensus price target of $39.20, suggesting a potential upside of 734.04%. Given Savara's higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Savara.
Summary
Sagimet Biosciences beats Savara on 9 of the 12 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
